enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Eli Lilly Scores FDA Approval For Eczema Treatment Ebglyss - AOL

   www.aol.com/eli-lilly-scores-fda-approval...

   Friday, the FDA approved Eli Lilly And Co’s (NYSE:LLY) Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least 88 pounds (40 ...

3. Tralokinumab - Wikipedia

   en.wikipedia.org/wiki/Tralokinumab

   A phase IIb study of tralokinumab found that treatment was associated with early and sustained improvements in atopic dermatitis symptoms and tralokinumab had an acceptable safety and tolerability profile, thereby providing evidence for targeting IL-13 in patients with atopic dermatitis. [21]

4. Interleukin 13 - Wikipedia

   en.wikipedia.org/wiki/Interleukin_13

   The secondary structural features of IL-13 are similar to that of Interleukin 4 (IL-4); however it only has 25% sequence identity to IL-4 and is capable of IL-4 independent signaling. [ 7 ] [ 4 ] [ 8 ] IL-13 is a cytokine secreted by T helper type 2 (Th2) cells, CD4 cells, natural killer T cell , mast cells , basophils , eosinophils and ...

5. Abrocitinib - Wikipedia

   en.wikipedia.org/wiki/Abrocitinib

   Two mechanisms are involved in atopic dermatitis, one involves epidermal barrier disruptions, and the other one is cutaneous inflammation due to the immune system over response. Acute inflammation in AD typically involves IL-13, IL-4, and IL-33. [17] Consequently, inhibiting JAK1 results in suppressing the signaling cytokines IL-4, IL-3, and IL-31.

6. Dupilumab - Wikipedia

   en.wikipedia.org/wiki/Dupilumab

   Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. [6] [7] [8] [4] It is also used for the treatment of eosinophilic esophagitis, [9] prurigo nodularis [10] and ...

7. Lebrikizumab - Wikipedia

   en.wikipedia.org/wiki/Lebrikizumab

   Lebrikizumab, sold under the brand name Ebglyss is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema). [7] [8] It is an interleukin-13 antagonist. [7] It is given by subcutaneous injection. [7]

8. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   clinical signs of atopic dermatitis in dogs [88] Lorvotuzumab mertansine: mab: humanized: CD56: cancer Lucatumumab [13] mab: human: CD40: multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma: Lulizumab pegol [6] mab: humanized: CD28: autoimmune diseases Lumiliximab [9] mab: chimeric: CD23 (IgE receptor) chronic lymphocytic leukemia ...

9. Oclacitinib - Wikipedia

   en.wikipedia.org/wiki/Oclacitinib

   [20] [21] IL-31 is a key cytokine at the pruritogenic receptors at neurons near the skin, and also induces peripheral blood mononuclear cells and keratinocytes to release pro-inflammatory cytokines. [16] Suppression of IL-4 and IL-13 causes a decrease of T h 2-cell differentiation, which plays a role in atopic dermatitis. [19]